COMT and Parkinsonism: The initial generation of COMT inhibitors was excessively toxic to be approved for use, but second-generation COMT inhibitors, including tolcapone (TOL), have been found to be effective in providing symptomatic relief for certain Parkinson’s patients with an acceptable toxicity profile.